What question did this study set out to answer?

The aim is to identify and optimize YTB53 as a potential therapy for acute myeloid leukemia (AML).

June 3, 2026

Discovery of YTB53, a Marine-Derived MNK-Active Anti-Acute Myeloid Leukemia Lead with Multi-Kinase Activity

Key Points

The aim is to identify and optimize YTB53 as a potential therapy for acute myeloid leukemia (AML).
Discovery of YTB53 through marine sources.
Evaluation of its anti-AML properties and kinase activity.
Plans for medicinal chemistry optimization to enhance pharmacokinetics.
YTB53 exhibits promising anti-AML activity.
Demonstrates multi-kinase activity relevant for AML treatment.

Abstract

as a promising multimechanistic lead for AML therapy, warranting further medicinal chemistry optimization to improve its pharmacokinetic properties and advance its development potential.

KI fragen

Bookmark

Cite This Study

Chen et al. (Mon,) studied this question.

synapsesocial.com/papers/6a1fc616dee9eb8c0dce746b https://doi.org/https://doi.org/10.1021/acs.jmedchem.6c00387

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

KI fragen

Bookmark